Few pharmacogenomics studies have looked at antiplatelet drugs in Brazilian cohorts, and they discovered relationships between CYP2C19*2, PON1 rs662, and ABCC3 rs757421 genotypes and platelet responsiveness or clopidogrel pharmacokinetic (PK) in participants suffered from CAD or acute coronary syndrome (ACS), whereas ITGB3 contributes to aspirin PK but not platelet responsiveness in diabetic individuals. Here, PON1 is linked to coronary artery disorder.